1521-4141/asset/2040_left.gif?v=1&s=92837c2f17424f89abf3f45e2642c107d62e6c04)
1521-4141/asset/EJI_right.gif?v=1&s=bce6d64154702bbe279104b1163baee31019fb77)
Highlights
IL-22 and inflammation: Leukin' through a glass onion
Article first published online: 14 NOV 2008
DOI: 10.1002/eji.200838655
Copyright © 2008 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
1521-4141/asset/cover.gif?v=1&s=1d17f8d1fcad107379391e28980b6bbc7e7758cf "European Journal of Immunology")
Additional Information
How to Cite
Zenewicz, L. A. and Flavell, R. A. (2008), IL-22 and inflammation: Leukin' through a glass onion. European Journal of Immunology, 38: 3265–3268. doi: 10.1002/eji.200838655
Publication History
- Issue published online: 27 NOV 2008
- Article first published online: 14 NOV 2008
- Manuscript Accepted: 29 SEP 2008
- Manuscript Revised: 18 SEP 2008
- Manuscript Received: 27 JUN 2008
Funded by
- American Liver Foundation
- American Cancer Society
- Abstract
- Article
- References
- Cited By
Keywords:
- Inflammation;
- IL-22;
- Th17 cells;
- Tissue responses
Abstract
IL-22 is a Th17 T-cell-associated cytokine that is highly expressed during chronic inflammation. IL-22 receptor expression is absent on immune cells, but is instead restricted to the tissues, providing signaling directionality from the immune system to the tissues. Through Stat3 signaling, IL-22 induces a variety of proliferative, anti-apoptotic, and anti-microbial pathways. IL-22 is bi-functional with both pro-inflammatory and protective effects on tissues depending on the inflammatory context. The cytokine plays a role both in the host response against extracellular pathogens and in the inflammation associated with autoimmune diseases. Therapeutics targeting IL-22 therefore may have promise for treating various chronic inflammatory diseases.